USP46 Inhibitors
USP46 inhibitors are a class of chemical compounds that specifically target and inhibit the enzymatic activity of ubiquitin-specific peptidase 46 (USP46), a deubiquitinating enzyme (DUB) within the ubiquitin-proteasome system. USP46 plays a significant role in the removal of ubiquitin from proteins, a process that can either prevent their degradation or regulate their function within the cell. By cleaving ubiquitin from target substrates, USP46 influences a range of cellular activities, including protein stability, signal transduction, and gene expression. Inhibitors of USP46 are designed to interfere with its ability to remove ubiquitin, thus impacting protein turnover and the overall regulation of ubiquitination processes in cells.
The molecular structure of USP46 inhibitors is designed to bind specifically to the catalytic domain of the enzyme, which is responsible for its deubiquitinating activity. These inhibitors can act by blocking the active site of USP46, preventing it from engaging with ubiquitinated substrates, or by stabilizing the enzyme in an inactive conformation. Some inhibitors may also interact with other regulatory regions of USP46, affecting its interactions with other proteins or cofactors that are necessary for its full enzymatic function. By inhibiting USP46, researchers can investigate its role in regulating the balance between protein synthesis and degradation, a fundamental aspect of cellular homeostasis. These inhibitors are essential tools for studying the dynamics of ubiquitination and the specific contribution of USP46 to processes such as protein quality control, cell cycle regulation, and intracellular signaling pathways. Through such research, scientists can gain a deeper understanding of how deubiquitinating enzymes like USP46 modulate complex biological networks.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132, a proteasome inhibitor, could promote the accumulation of ubiquitinated transcription factors that, when not degraded, may actively repress USP46 gene transcription. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $36.00 $68.00 $107.00 $214.00 $234.00 $862.00 $1968.00 | 47 | |
Curcumin has been shown to downregulate the expression of specific genes by inhibiting the activation of nuclear factor-kappa B (NF-κB), which could lead to decreased transcription of USP46. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $60.00 $185.00 $365.00 | 64 | |
Resveratrol may downregulate USP46 expression by activating sirtuins, leading to alterations in the histone acetylation patterns of the USP46 gene promoter, rendering it less accessible for transcription. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059, by inhibiting MEK1/2, could suppress the ERK pathway, which may be necessary for the initiation of USP46 gene transcription, leading to reduced expression levels. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
Fluorouracil, a thymidylate synthase inhibitor, may lead to a shortage of thymidine triphosphate for DNA synthesis, potentially resulting in lowered transcriptional rates of genes including USP46. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $88.00 $200.00 | 13 | |
Triptolide may directly bind to transcriptional machinery, hindering the elongation of transcripts and thus leading to a decrease in USP46 mRNA synthesis. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid may induce hyperacetylation of histones associated with the USP46 gene promoter, potentially leading to the repression of its initiation complex formation and subsequent reduction in USP46 expression. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide could disrupt the transcription factor IκB kinase (IKK) complex, lowering NF-κB activity, which might be responsible for driving the transcription of USP46, thus reducing its expression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin may inhibit mTORC1 signaling, which is essential for cap-dependent translation initiation; this could lead to a decrease in the synthesis of proteins necessary for USP46 transcription. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $30.00 $46.00 $82.00 $218.00 | 19 | |
Sodium Butyrate, by inhibiting histone deacetylases, may cause an accumulation of acetylated histones at the USP46 promoter, which can repress gene transcription, thus reducing USP46 expression. | ||||||